Results 41 to 50 of about 72,405 (280)

Essential Updates in the Surgical Management of Inflammatory Bowel Disease: Current Topics From 2024 to Mid‐2026

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Inflammatory bowel disease management has undergone a major transformation with the introduction of treat‐to‐target strategies and highly effective biologic and small‐molecule therapies. Although these advances have reduced the overall requirement for surgery, operative intervention remains essential for selected patients with ulcerative ...
Yoshiki Okita   +4 more
wiley   +1 more source

Determinants of Difficult‐to‐Manage and Treatment‐Refractory Axial Spondyloarthritis: A Cross‐Sectional Analysis Within a Longitudinal Cohort

open access: yesArthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to estimate the prevalence of difficult‐to‐manage (D2M) and treatment‐refractory (TR) axial spondyloarthritis (axSpA) and to identify factors associated with D2M and TR disease in a longitudinal cohort. Methods We performed a cross‐sectional analysis on data from the Schroeder Arthritis Institute Spondylitis ...
Patricia Remalante‐Rayco   +8 more
wiley   +1 more source

A Rare Case of Leukocytoclastic Vasculitis Associated With Infliximab

open access: yes, 2023
Infliximab is a chimeric monoclonal antibody to tumor necrosis factor-α used commonly in several autoimmune conditions including Crohn’s disease. We present a case of a 33-year-old man with inflammatory ileocolonic Crohn’s disease who developed biopsy ...
Angela Wu, Uni Wong, Danielle Brown
core   +1 more source

External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease

open access: yesPharmaceutics, 2021
Infliximab is approved for treatment of various chronic inflammatory diseases including inflammatory bowel disease (IBD). However, high variability in infliximab trough levels has been associated with diverse response rates.
Christina Schräpel   +7 more
doaj   +1 more source

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner   +52 more
wiley   +1 more source

Effect of Systemic Infliximab Therapy in Patients with Sjögren’s Syndrome

open access: yes, 2015
Objectives: To investigate the effect of systemic infliximab therapy on tear function tests and the ocular surface in patients with Sjögren’s syndrome secondary to various autoimmune diseases.
Serpil Tuna   +2 more
core   +1 more source

Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions

open access: yesArthritis &Rheumatology, EarlyView.
Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson   +127 more
wiley   +1 more source

Human Monocytic Models Reveal Genotype‐Dependent Inflammatory Programs in VEXAS Syndrome

open access: yesArthritis &Rheumatology, EarlyView.
Objective VEXAS syndrome is a severe X‐linked autoinflammatory disorder caused by somatic mutations in ubiquitin‐like modifier activating enzyme 1 (UBA1), with clinical outcomes that vary by UBA1 genotype. We aimed to elucidate genotype‐specific inflammatory programs and identify potential therapeutic targets.
Kana Higashitani   +10 more
wiley   +1 more source

Plasma Proteomics Identifies Molecular Signatures and Biomarkers Associated With High Structural Damage in Ankylosing Spondylitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Pathologic bone formation in ankylosing spondylitis (AS) is not fully reflected by systemic inflammation, limiting the utility of markers of inflammation for structural damage assessment. This study aimed to identify plasma protein signatures associated with structural damage severity in AS.
Tiantian Sun   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy